- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04644770
Eine Studie zu JNJ-69086420, einem mit Actinium-225 markierten Antikörper gegen humanes Kallikrein-2 (hK2) bei fortgeschrittenem Prostatakrebs
Eine Phase-1-Studie zu JNJ-69086420, einem Actinium-225-markierten Antikörper, der auf humanes Kallikrein-2 (hK2) bei fortgeschrittenem Prostatakrebs abzielt
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-69086420 in Part 1 (Dose Escalation), to determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose Expansion), to determine safety of JNJ-69086420 at the RP2D(s) as a combination therapy in Part 3 (combination therapy) and to determine safety of JNJ-69086420 at the RP2D(s) in participants with metastatic hormone-sensitive prostate cancer (mHSPC) in Part 4.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85054
- Mayo Clinic Arizona
-
-
California
-
Duarte, California, Vereinigte Staaten, 91010
- City of Hope
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32224
- Mayo Clinic in Florida
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60637
- University of Chicago
-
-
Louisiana
-
Metairie, Louisiana, Vereinigte Staaten, 70006
- East Jefferson General Hospital
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Tulane University Hospital & Clinics
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Mayo Clinic Rochester
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68130
- XCancer Omaha / Urology Cancer Center
-
-
New York
-
New York, New York, Vereinigte Staaten, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Case Western Reserve University
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84112
- University of Utah Huntsman Cancer Institute
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- For Part 1, Part 2, Part 3: Metastatic castration resistant prostate cancer (mCRPC) with histologic confirmation of adenocarcinoma (adenocarcinoma with small-cell or neuroendocrine features is allowed) with prior exposure to at least one androgen receptor (AR) targeted therapy (for example [e.g.], abiraterone acetate, enzalutamide, apalutamide, darolutamide). In addition: Part 1: prior taxane or other chemotherapy is acceptable but not required. Part 2a: prior taxane or other chemotherapy required, Part 2b: no prior taxane or other chemotherapy, Part 2c: mCRPC that has progressed after prior treatment with lutetium Lu-177 vipivotide tetraxetan, with or without prior chemotherapy, Part 3: prior taxane or other chemotherapy is acceptable but not required & For Part 4a: metastatic HSPC, For Part 4b: disease that can be treated with less than or equal to (<=) 5 radiation fields and no visceral metastases
- Parts 1, 2 & 3: Prior orchiectomy or medical castration, or, for participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analog (agonist or antagonist) prior to the first dose of study drug and must continue this therapy throughout the treatment phase. This criterion does not apply to Part 4
- Palliative radiotherapy (e.g. soft tissue lesions) must be completed greater than (>) 2 weeks prior to start of study drug except for palliative radiotherapy for pain (e.g., bone pain), which may be used any time prior to first dose
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ functions as reflected in laboratory parameters
Exclusion Criteria:
- Prior treatment with radium Xofigo (Ra 223 dichloride), strontium, samarium, or other radioconjugate therapy, other systemic anti-neoplastic therapy <=30 days prior to the first dose of study drug except for luteinizing hormone-releasing hormone agonists/antagonists or GnRH agonists/antagonists. Novel androgen axis drugs <=14 days prior to the first dose of study drug. In addition: Part 2b: Must not have received prior treatment with chemotherapy (eg, docetaxel) or poly ADP ribose polymerase (PARP) inhibitors, Part 2c: Prior treatment with lutetium Lu-177 vipivotide tetraxetan is required, but must have been completed >42 days prior to first dose of study drug, Part 3: Must not have received prior treatment with JNJ-78278343, Part 4: Must not have received ADT or AR-targeted therapy less than or equal to (<=) 56 days prior to first dose of study drug
- Known history of myelodysplastic syndrome, leukemia, or hematological malignancy with features suggestive of myelodysplastic syndrome/acute myeloid leukemia at any timepoint
- Toxicity from prior anticancer therapy has not resolved to baseline levels or to Grade <= 1 (except alopecia, radiation tissue fibrosis, or peripheral neuropathy)
- Known allergies, hypersensitivity, or intolerance to JNJ-69086420 or its excipients and protein therapeutics. For Part 3, known allergies, hypersensitivity, or intolerance to JNJ-78278343 or its excipients or protein therapeutics
- Active or chronic hepatitis B or hepatitis C infection
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Part 1: Dose Escalation
Participants will receive JNJ-69086420 with one or multiple doses. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified. |
Participants will receive JNJ-69086420.
Andere Namen:
|
|
Experimental: Part 2: Dose Expansion
Participants in one or more cohorts will receive JNJ-69086420 at the RP2D(s) determined in Part 1. |
Participants will receive JNJ-69086420.
Andere Namen:
|
|
Experimental: Part 3: Combination Therapy
Participants will receive JNJ-69086420 at the determined RP2D(s) and fixed dose of JNJ-78278343. |
Participants will receive JNJ-69086420.
Andere Namen:
Participants will receive JNJ-78278343. |
|
Experimental: Part 4: HSPC Expansion
Participants with HSPC will receive JNJ-69086420 at the RP2D(s) in Part 4(a), and JNJ-69086420 following stereotactic body radiation therapy in Part 4(b). |
Participants will receive JNJ-69086420.
Andere Namen:
Participants will receive stereotactic body radiaition therapy. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
Zeitfenster: Up to 2 years and 4 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 2 years and 4 months
|
|
Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)
Zeitfenster: Up to 2 years and 4 months
|
Number of participants with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity. |
Up to 2 years and 4 months
|
|
Number of Participants with AEs by Severity
Zeitfenster: Up to 2 years and 4 months
|
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
Up to 2 years and 4 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants with Prostate Specific Antigen (PSA) Response
Zeitfenster: Up to 2 years and 4 months
|
PSA response rate is defined as the percentage of participants with a decline of PSA of 50 percent (%) or more from baseline and that is subsequently confirmed. |
Up to 2 years and 4 months
|
|
Overall Response Rate (ORR)
Zeitfenster: Up to 2 years and 4 months
|
ORR is defined as the percentage of participants who have a Partial Response (PR) or better according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 without evidence of bone progression according to Prostate Cancer Working Group 3 (PCWG3). |
Up to 2 years and 4 months
|
|
Maximum Observed Serum Concentration/Radioactivity (Cmax) of JNJ-69086420
Zeitfenster: Up to 2 years and 4 months
|
Cmax is defined as the maximum observed serum concentration/radioactivity of JNJ-69086420. |
Up to 2 years and 4 months
|
|
Time to Reach Maximum Observed Serum Concentration/Radioactivity (Tmax) of JNJ-69086420
Zeitfenster: Up to 2 years and 4 months
|
Tmax is defined as time to reach maximum observed serum concentration/radioactivity of JNJ-69086420. |
Up to 2 years and 4 months
|
|
Area Under the Serum Concentration-time Curve From Time Zero to t Time (AUC[0-t]) of JNJ-69086420
Zeitfenster: Up to 2 years and 4 months
|
AUC(0-t) is defined as the area under the serum concentration-time curve from time zero to t of JNJ-69086420. |
Up to 2 years and 4 months
|
|
Number of Participants With Anti-JNJ-69086420 Antibodies
Zeitfenster: Up to 2 years and 4 months
|
Number of participants with anti-JNJ-69086420 antibodies will be assessed to evaluate the potential immunogenicity. |
Up to 2 years and 4 months
|
|
Part 3: Serum Concentration of JNJ-78278343
Zeitfenster: Up to 2 years and 4 months
|
Venous blood samples will be collected for assessment of serum concentrations of JNJ-78278343. |
Up to 2 years and 4 months
|
|
Part 3:Number of Participants With Anti-JNJ-78278343 Antibodies
Zeitfenster: Up to 2 years and 4 months
|
Number of participants with anti-JNJ-78278343 antibodies will be assessed to evaluate the potential immunogenicity. |
Up to 2 years and 4 months
|
Mitarbeiter und Ermittler
Ermittler
- Studienleiter: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Genitale Neubildungen, männlich
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Genitalerkrankungen, männlich
- Prostataerkrankungen
- Männliche Urogenitalerkrankungen
- Neubildungen nach histologischem Typ
- Neubildungen, Drüsen und Epithelien
- Karzinom
- Prostataneoplasmen
- Adenokarzinom
- Untersuchungstechniken
- Therapeutika
- Chirurgische Eingriffe, operativ
- Strahlentherapie
- Stereotaktische Techniken
- Neurochirurgische Verfahren
- Radiochirurgie
Andere Studien-ID-Nummern
- CR108817
- 69086420PCR1001 (Andere Kennung: Janssen Research & Development, LLC)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .